Skip to main content
Top
Published in: Endocrine 3/2020

01-09-2020 | Diabetic Retinopathy | Original Article

Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c

Authors: Pegah Khaloo, Reihane Qahremani, Soghra Rabizadeh, Mohammad Omidi, Armin Rajab, Firouzeh Heidari, Ghasem Farahmand, Masoume Bitaraf, Hossein Mirmiranpour, Alireza Esteghamati, Manouchehr Nakhjavani

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

Purpose

Regarding the role of inflammation in progression of diabetes this study was conducted to investigate the association between inflammatory biomarkers such as nitric oxide (NO), tumor necrosis factor alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) with the chance of existence of diabetic retinopathy and its progression in patients with diabetes.

Methods

A total of 83 patients with T2DM (Type 2 diabetes mellitus) were divided into three groups of patients with proliferative diabetic retinopathy (PDR), patients with non-proliferative diabetic retinopathy (NPDR) and patients without diabetic retinopathy (NDR) based on ophthalmologic funduscopic examination. Twenty six healthy controls were also enrolled. Blood samples were taken after 12 h of overnight fasting, NO, TNF-α, and hs-CRP were measured. Association of the level of these biomarkers with retinopathy was analyzed.

Results

The levels of TNF-α, NO and hs-CRP were higher among patients with diabetic retinopathy. Multinomial Logistic Regression model showed that TNF-α and NO could predict the presence of retinopathy among patients with diabetes when adjusted for hs-CRP, HbA1c, FBS, gender, total cholesterol, triglyceride, HDL, LDL, BMI, and age (respectively OR = 1.76, CI 95% = 1.01–3.02, p = 0.046 and OR = 1.12, CI 95% = 1.05–1.18, p < 0.001); however they could not predict the severity of retinopathy. In ROC analysis AUC for TNFα was 0.849 (p < 0.001) and for NO was 0.907 (p < 0.001). Serum TNF-α level of 7.10 pmol/L could be suggestive of the presence of retinopathy (sensitivity = 92.2% and specificity = 66.0%), also serum NO level of 45.96 μmol/L could be suggestive of the presence of retinopathy (sensitivity = 96.1% and specificity = 86%).

Conclusions

Our results suggest elevated levels of NO and TNF-α can be suggestive of diabetic retinopathy.
Literature
1.
go back to reference Y. Behl et al. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol. 172(5), 1411–1418 (2008)CrossRef Y. Behl et al. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol. 172(5), 1411–1418 (2008)CrossRef
2.
go back to reference M.V. van Hecke et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 48(7), 1300–1306 (2005)CrossRef M.V. van Hecke et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 48(7), 1300–1306 (2005)CrossRef
3.
go back to reference A.M. Spijkerman et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabet Med. 24(9), 969–976 (2007)CrossRef A.M. Spijkerman et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabet Med. 24(9), 969–976 (2007)CrossRef
4.
go back to reference T.S. Kern, Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 95103 (2007)CrossRef T.S. Kern, Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 95103 (2007)CrossRef
5.
go back to reference K. Zorena et al. Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Med. Inflamm. 2007, 92196–92196 (2007)CrossRef K. Zorena et al. Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Med. Inflamm. 2007, 92196–92196 (2007)CrossRef
6.
go back to reference D. Ray et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53(3), 861 (2004)CrossRef D. Ray et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53(3), 861 (2004)CrossRef
7.
go back to reference A.M. Joussen et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 16(3), 438–440 (2002)CrossRef A.M. Joussen et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 16(3), 438–440 (2002)CrossRef
8.
go back to reference R. Arita et al. A key role for ROCK in TNF-α–mediated diabetic microvascular damage. Investig. Ophthalmol. Vis. Sci. 54(3), 2373–2383 (2013)CrossRef R. Arita et al. A key role for ROCK in TNF-α–mediated diabetic microvascular damage. Investig. Ophthalmol. Vis. Sci. 54(3), 2373–2383 (2013)CrossRef
9.
go back to reference M. Torzewski et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20(9), 2094–2099 (2000)CrossRef M. Torzewski et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20(9), 2094–2099 (2000)CrossRef
10.
go back to reference A.R. Tall, C-reactive protein reassessed. N. Engl. J. Med. 350(14), 1450–1452 (2004)CrossRef A.R. Tall, C-reactive protein reassessed. N. Engl. J. Med. 350(14), 1450–1452 (2004)CrossRef
11.
go back to reference J. Song et al. Relationship between C-reactive protein level and diabetic retinopathy: a systematic review and meta-analysis. PLoS ONE 10(12), e0144406 (2015)CrossRef J. Song et al. Relationship between C-reactive protein level and diabetic retinopathy: a systematic review and meta-analysis. PLoS ONE 10(12), e0144406 (2015)CrossRef
12.
go back to reference W. Zhang et al. Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy 3(5), 609–628 (2011)CrossRef W. Zhang et al. Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy 3(5), 609–628 (2011)CrossRef
13.
go back to reference Q. Li et al. Diabetic eNOS-knockout mice develop accelerated retinopathy. Investig. Ophthalmol. Vis. Sci. 51(10), 5240–5246 (2010)CrossRef Q. Li et al. Diabetic eNOS-knockout mice develop accelerated retinopathy. Investig. Ophthalmol. Vis. Sci. 51(10), 5240–5246 (2010)CrossRef
14.
go back to reference A.M. Abu El-Asrar et al. Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye 18(3), 306–313 (2004)CrossRef A.M. Abu El-Asrar et al. Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye 18(3), 306–313 (2004)CrossRef
15.
go back to reference G.K. Kolluru, S.C. Bir, C.G. Kevil, Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int. J. Vasc. Med. 2012, 30 (2012) G.K. Kolluru, S.C. Bir, C.G. Kevil, Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int. J. Vasc. Med. 2012, 30 (2012)
16.
go back to reference American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes. Diabetes Care, 42(Supplement 1), S13 (2019) American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes. Diabetes Care, 42(Supplement 1), S13 (2019)
17.
go back to reference G.S. Hotamisligil, B.M. Spiegelman, Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43(11), 1271–1278 (1994)CrossRef G.S. Hotamisligil, B.M. Spiegelman, Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43(11), 1271–1278 (1994)CrossRef
18.
go back to reference G.S. Hotamisligil et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Investig. 95(5), 2409–2415 (1995)CrossRef G.S. Hotamisligil et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Investig. 95(5), 2409–2415 (1995)CrossRef
19.
go back to reference P.A. Kern et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Investig. 95(5), 2111–2119 (1995)CrossRef P.A. Kern et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Investig. 95(5), 2111–2119 (1995)CrossRef
20.
go back to reference P. Peraldi et al. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J. Biol. Chem. 271(22), 13018–13022 (1996)CrossRef P. Peraldi et al. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J. Biol. Chem. 271(22), 13018–13022 (1996)CrossRef
21.
go back to reference F. Balkwill, TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25(3), 409–416 (2006)CrossRef F. Balkwill, TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25(3), 409–416 (2006)CrossRef
22.
go back to reference M.J. Tisdale, Cancer cachexia. Langenbecks Arch. Surg. 389(4), 299–305. (2004)CrossRef M.J. Tisdale, Cancer cachexia. Langenbecks Arch. Surg. 389(4), 299–305. (2004)CrossRef
23.
go back to reference A.M. Joussen et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 15, 1418–1428 (2009)PubMedPubMedCentral A.M. Joussen et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 15, 1418–1428 (2009)PubMedPubMedCentral
24.
go back to reference S. Doganay et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16(2), 163–170 (2002)CrossRef S. Doganay et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16(2), 163–170 (2002)CrossRef
25.
go back to reference N. Makino et al. High serum TNF-α level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J. Diabetes Complicat. 19(6), 347–355 (2005)CrossRef N. Makino et al. High serum TNF-α level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J. Diabetes Complicat. 19(6), 347–355 (2005)CrossRef
26.
go back to reference D.N. Koleva-Georgieva, N.P. Sivkova, D. Terzieva, Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med. 53(2), 44–50 (2011) D.N. Koleva-Georgieva, N.P. Sivkova, D. Terzieva, Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med. 53(2), 44–50 (2011)
27.
go back to reference H. Kaneto et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 44(7), 733–738 (1995)CrossRef H. Kaneto et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 44(7), 733–738 (1995)CrossRef
28.
go back to reference M.L. McDaniel et al. Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med. 211(1), 24–32 (1996)CrossRef M.L. McDaniel et al. Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med. 211(1), 24–32 (1996)CrossRef
29.
go back to reference T.J. Guzik, R. Korbut, T. Adamek-Guzik, Nitric oxide and superoxide in inflammation and immune regulation. J. Physiol. Pharmacol. 54(4), 469–487 (2003)PubMed T.J. Guzik, R. Korbut, T. Adamek-Guzik, Nitric oxide and superoxide in inflammation and immune regulation. J. Physiol. Pharmacol. 54(4), 469–487 (2003)PubMed
30.
go back to reference Z. Davoudi et al. Changing correlations among ADMA, NO and hs-CRP in normoalbuminuric and microalbuminuric patients with type 2 diabetes. Meta Gene 10, 95–99 (2016)CrossRef Z. Davoudi et al. Changing correlations among ADMA, NO and hs-CRP in normoalbuminuric and microalbuminuric patients with type 2 diabetes. Meta Gene 10, 95–99 (2016)CrossRef
31.
go back to reference J.L. Wilkinson-Berka, Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des. 10(27), 3331–3348 (2004)CrossRef J.L. Wilkinson-Berka, Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des. 10(27), 3331–3348 (2004)CrossRef
32.
go back to reference E.C. Leal et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 48(11), 5257–5265 (2007)CrossRef E.C. Leal et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 48(11), 5257–5265 (2007)CrossRef
33.
go back to reference P.S. Chan, M. Kanwar, R.A. Kowluru, Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J. Diabetes Complicat. 24(1), 55–63 (2010)CrossRef P.S. Chan, M. Kanwar, R.A. Kowluru, Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J. Diabetes Complicat. 24(1), 55–63 (2010)CrossRef
34.
go back to reference M. Manju et al. Relationship between glycosylated hemoglobin, serum nitric oxide and mean arterial blood pressure. Int. J. Biomed. Sci. 10(4), 252–257 (2014)PubMedPubMedCentral M. Manju et al. Relationship between glycosylated hemoglobin, serum nitric oxide and mean arterial blood pressure. Int. J. Biomed. Sci. 10(4), 252–257 (2014)PubMedPubMedCentral
35.
go back to reference A. Ghosh et al. Serum nitric oxide status in patients with type 2 diabetes mellitus in Sikkim. Int. J. Appl. Basic Med. Res. 1(1), 31–35 (2011)CrossRef A. Ghosh et al. Serum nitric oxide status in patients with type 2 diabetes mellitus in Sikkim. Int. J. Appl. Basic Med. Res. 1(1), 31–35 (2011)CrossRef
36.
go back to reference D. Tousoulis et al. The role of nitric oxide on endothelial function. Curr. Vasc. Pharmacol. 10(1), 4–18 (2012)CrossRef D. Tousoulis et al. The role of nitric oxide on endothelial function. Curr. Vasc. Pharmacol. 10(1), 4–18 (2012)CrossRef
37.
go back to reference A.M. El-Asrar, Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr. J. Ophthalmol. 19(1), 70–74 (2012)CrossRef A.M. El-Asrar, Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr. J. Ophthalmol. 19(1), 70–74 (2012)CrossRef
38.
go back to reference T.S. Assmann et al. Nitric oxide levels in patients with diabetes mellitus: a systematic review and meta-analysis. Nitric Oxide 61, 1–9 (2016)CrossRef T.S. Assmann et al. Nitric oxide levels in patients with diabetes mellitus: a systematic review and meta-analysis. Nitric Oxide 61, 1–9 (2016)CrossRef
39.
go back to reference A.N.N. Mertens, P. Holvoet, Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 15(12), 2073–2084 (2001)CrossRef A.N.N. Mertens, P. Holvoet, Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 15(12), 2073–2084 (2001)CrossRef
Metadata
Title
Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c
Authors
Pegah Khaloo
Reihane Qahremani
Soghra Rabizadeh
Mohammad Omidi
Armin Rajab
Firouzeh Heidari
Ghasem Farahmand
Masoume Bitaraf
Hossein Mirmiranpour
Alireza Esteghamati
Manouchehr Nakhjavani
Publication date
01-09-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02353-x

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.